

PG3733USW

--10. A method for the preparation of a medicament for use as a muscle relaxant, fever reducer, or anxiolytic; use in migraine, bipolar disorder, unipolar depression, functional bowel disorders, or tinnitus; use in preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence-inducing agent; use in cancerous diseases, inflammatory processes, or ophthalmic diseases; and use as an analgesic comprising using a KCNQ2/3 potassium channel opener.--

--11. A method for producing a muscle relaxant, fever reducer, or anxiolytic; for treating migraine, bipolar disorder, unipolar depression, functional bowel disorders, or tinnitus; for preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence-inducing agent; for treating cancerous diseases, inflammatory processes, or ophthalmic diseases; or for producing an analgesic effect; in a mammal, including man, comprising administration of an effective amount of a KCNQ2/3 potassium channel opener.--

--12. A method for the preparation of a medicament for the treatment of conditions ameliorated by KCNQ2/3 potassium channel opening comprising using retigabine.--

--13. A method for the preparation of a medicament for use in neurotransmission disorders; CNS disorders; functional bowel disorders; neurodegenerative diseases; neuroprotection; tinnitus; preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence – inducing agent; cancerous diseases; inflammatory processes; ophthalmic diseases; cognitive disorders; and migraine; and or as a centrally acting analgesic comprising using retigabine.--

PG3733USW

--14. A method for the treatment of neurotransmission disorders, CNS disorders, functional bowel disorders, neurodegenerative diseases, or tinnitus; preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence – inducing agent; the treatment of cancerous diseases, inflammatory processes, ophthalmic diseases, cognitive disorders, or migraine; and producing a neuroprotecting, or a centrally acting analgesic effect; in a mammal, including man, comprising administration of an effective amount of retigabine.--